Results 151 to 160 of about 7,679 (193)

Using machine learning to define mepolizumab treatment response at 2 years in patients with chronic rhinosinusitis with nasal polyps. [PDF]

Front Allergy
Domínguez-Sosa MS, Cabrera-Ramírez MS, Marrero-Ramos MDC, Cabrera-López C, Carrillo-Díaz T, Benítez-Rosario J, Dávila-Quintana CD.   +6 more
europepmc   +1 more source

Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature. [PDF]

Rheumatol Int
Sebastian A, Kosałka-Węgiel J, Puchala M, Życińska K, Kolarz B, Bieniasz-Pawlik E, Korkosz M.   +6 more
europepmc   +1 more source

Trends of T2 and Non-T2 Cytokines During Mepolizumab Treatment in Different Asthma Patient Subgroups. [PDF]

Biomedicines
Zurlo M, Ambrosani F, Maule M, Cheema NA, Mascia F, Aparo A, Argentino G, Vaia R, Baiocchi A, Senna G, Friso S, Castagna A, Caminati M.   +12 more
europepmc   +1 more source

Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. [PDF]

Front Immunol
Ou W, Wang Y, Hou C, Hou S, Zhou Y, Wang J, Wang Q.   +6 more
europepmc   +1 more source

A Case of Eosinophilic Granulomatosis with Polyangiitis Emerging During Benralizumab Therapy: Successful Management Through a Switch to Mepolizumab Therapy. [PDF]

J Asthma Allergy
Saito Y, Ito J, Watanabe T, Tanabe Y, Sasano H, Sato Y, Jingo K, Nishimaki T, Matsuno K, Takahashi K, Harada N.   +10 more
europepmc   +1 more source

Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation. [PDF]

BMC Pulm Med
Buendía JA, Guerrero Patiño D, Muñoz Mejia O, Celis Preciado C.   +3 more
europepmc   +1 more source

Eosinophilic myocarditis: diagnostic pitfalls and therapeutic challenges. A Case Series. [PDF]

Front Cardiovasc Med
Giordani AS, Menghi C, Baritussio A, Scognamiglio F, Vicenzetto C, Castegnaro M, Marcolongo R, Toscano G, Chieco Bianchi F, Iorio L, Padoan R, De Gaspari M, Rizzo S, Basso C, Caforio ALP.   +14 more
europepmc   +1 more source

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma. [PDF]

Cureus
Fujimoto M, Yanagihara T, Sakaki Y, Fujita M.   +3 more
europepmc   +1 more source

Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study. [PDF]

J Asthma Allergy
Vergles M, Salai G, Tudorić N, Kovačević I, Kifer D, Lalić K, Gomerčić Palčić M, Vukić Dugac A.   +7 more
europepmc   +1 more source

Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost-effectiveness analysis. [PDF]

J Comp Eff Res
Yang J, Ren L, Xie F, Shao R, Jiang R.
europepmc   +1 more source